United Therapeutics Corporation

Equities

UTHR

US91307C1027

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 23/07/2024 BST 5-day change 1st Jan Change
336.74 USD +1.24% Intraday chart for United Therapeutics Corporation +2.61% +53.14%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
United Therapeutics Insider Sold Shares Worth $2,355,544, According to a Recent SEC Filing MT
TD Cowen Adjusts Price Target on United Therapeutics to $350 From $270, Maintains Buy Rating MT
Everything's going according to plan Our Logo
Morgan Stanley Downgrades United Therapeutics to Equalweight From Overweight, Adjusts PT to $321 From $310 MT
Analyst recommendations: Albemarle, Levi Strauss & Co, On Semiconductor, Spotify, Costco... Our Logo
United Therapeutics Says Idiopathic Pulmonary Fibrosis Treatment Study Reaches Full Enrollment MT
United Therapeutics Corporation Announces Full Enrollment of the TETON 2 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis CI
UBS Adjusts Price Target on United Therapeutics to $370 From $300, Maintains Buy Rating MT
United Therapeutics Corporation(NasdaqGS:UTHR) added to Russell 1000 Defensive Index CI
United Therapeutics Corporation(NasdaqGS:UTHR) added to Russell 1000 Value-Defensive Index CI
United Therapeutics Insider Sold Shares Worth $2,395,035, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $2,285,941, According to a Recent SEC Filing MT
United Therapeutics Corporation Announces Board Changes CI
Tempus, United Therapeutics Launch Collaboration to Use AI to Detect Risk of Pulmonary Hypertension MT
Tempus AI, Inc. Announces Collaboration with United Therapeutics to Study Use of AI to Detect Patients at Risk for Pulmonary Hypertension CI
United Therapeutics Insider Sold Shares Worth $1,033,984, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $1,027,716, According to a Recent SEC Filing MT
Transcript : United Therapeutics Corporation Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 04:00 PM
Wells Fargo Raises Price Target on United Therapeutics to $350 From $325, Maintains Overweight Rating MT
Liquidia's Yutrepia Launch Cleared as Court Denies Injunction MT
United Therapeutics Insider Sold Shares Worth $545,800, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $1,911,532, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $1,898,393, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $949,737, According to a Recent SEC Filing MT
United Therapeutics Insider Sold Shares Worth $1,871,233, According to a Recent SEC Filing MT
Chart United Therapeutics Corporation
More charts
Logo United Therapeutics Corporation
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder.
Employees
1,168
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
336.74USD
Average target price
314.94USD
Spread / Average Target
-6.47%
Consensus
  1. Stock Market
  2. Equities
  3. UTHR Stock
  4. News United Therapeutics Corporation
  5. United Therapeutics Insider Sold Shares Worth $545,800, According to a Recent SEC Filing